Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=principal_investigator" }, "data": [ { "type": "Grant", "id": "15236", "attributes": { "award_id": "1K08AI178093-01A1", "title": "SARS-CoV-2 immune responses in patients with lymphoma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6125, "first_name": "Timothy A.", "last_name": "Gondre-Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-23", "end_date": "2029-07-31", "award_amount": 192888, "principal_investigator": { "id": 31821, "first_name": "Andres", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients have immune system deficits that arise from the cancer and are aggravated by lymphoma therapies, placing them at higher risk of morbidity and mortality after infection with viruses like influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients are strongly recommended to get vaccinated and boosted with SARS-CoV-2 mRNA vaccines, but antibody responses after vaccination in these patients are often impaired. SARS-CoV-2 vaccines also elicit T cell responses in healthy individuals that may be protective but previous studies indicate that T cells from NHL/CLL patients are also dysfunctional. Under the mentorship of Drs. Rafi Ahmed and Jonathon Cohen, I have assembled a cohort of over 600 NHL/CLL patients with over 1,300 longitudinal blood samples paired with clinical data that I have used to study the immune responses in this patient population. Using this cohort, I showed that most patients have lower antibody responses after SARS-CoV-2 vaccination than otherwise healthy individuals and that antibody responses correlate at least partly with lymphoma therapies. I have also shown that some patients produce spike-specific CD4+ and CD8+ T cells after vaccination. The longitudinal, antigen-specific CD4+ and CD8+ T cell responses after vaccination and infection have not been well characterized in NHL/CLL patients. I hypothesize that these patients have alterations in their CD4+ and CD8+ T cell responses after antigen stimulation, which are dependent on the underlying lymphoma subtype and lymphoma therapy. This proposal has 3 goals: 1) To evaluate the generation, differentiation, breadth, and persistence of SARS- CoV-2-specific CD4+ T cell responses in NHL/CLL patients after vaccination and infection using functional assays and single cell sequencing technologies; 2) To define the primary and memory SARS-CoV-2-specific CD8+ T cell responses after vaccination and infection through functional assays and single cell sequencing technologies; and 3) to support my transition from a trainee in Dr. Ahmed’s laboratory to leading an independent research program. Successful completion of these studies will provide in-depth knowledge of the generation, evolution, breadth, and persistence of antigen-specific T cell responses in NHL/CLL patients after vaccination and infection. This knowledge will facilitate the design of interventions that may improve vaccine responses in these and other immunosuppressed patients, protecting them from potentially life-threatening viral infections like SARS-CoV-2 and influenza. Moreover, the insights on the generation and maintenance of adaptive immune responses against novel antigens obtained from these studies could help fuel the development of better cancer immunotherapies.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15237", "attributes": { "award_id": "1R21DE033170-01A1", "title": "ACE2-independent alternative receptors for SARS-CoV-2 at the oral mucosa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Dental and Craniofacial Research (NIDCR)" ], "program_reference_codes": [], "program_officials": [ { "id": 22517, "first_name": "Preethi", "last_name": "Chander", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 235500, "principal_investigator": { "id": 31822, "first_name": "Theresa L", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1856, "ror": "", "name": "RUTGERS BIOMEDICAL AND HEALTH SCIENCES", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major challenge for public health since the first case was reported in December 2019. In May 2023, the WHO and CDC marked the end of the COVID-19 public health emergency. However, COVID-19 remains a threat due to continuously evolving new variants, and fully vaccinated people remain susceptible to infection by the newer variants of the virus. SARS-CoV-2 entry is primarily mediated by binding of the SARS-CoV-2 spike protein (receptor-binding domain, RBD) to the human angiotensin-converting enzyme 2 (ACE2) receptor. Although ACE2-expressing cells support robust SARS-CoV-2 viral replication, ACE2 expression profiles are not completely associated with clinical manifestations or immune responses. Furthermore, SARS-CoV-2 infects organs or cells that do not express ACE2, suggesting the involvement of alternative receptors for SARS-CoV-2. Our and other laboratories have identified ACE2-independent alternative receptors for SARS-CoV-2, and infection via alternative receptors (e.g. CD147) is resistant to monoclonal antibodies against spike RBD, which is the target for several SARS-CoV-2 vaccines to block ACE2 binding. Our preliminary data show that oral epithelial, salivary gland, and gingival epithelial cells are susceptible to the replication-competent SARS-CoV-2 and pseudotyped SARS-CoV-2 Omicron variant despite low or undetectable expression of ACE2. These oral epithelial cells do however express high levels of alternative receptors CD147 or AXL, suggesting the role of alternative receptors in SARS-CoV-2 infection of oral epithelial cells. We hypothesize that these alternative receptors play a critical role in SARS-CoV-2 infection and virus-mediated immune activation in region-specific oral epithelial cells. In Aim 1, we will determine repertories of receptors for SARS-CoV-2 and infection profiles in region-specific oral epithelial cells and tissues from healthy subjects and subjects with oral inflammation pre- and post-treatment. In Aim 2, we will determine the contribution of specific receptors to SARS-CoV-2 infection and virus-mediated immune activation in oral epithelial cells. Considering that the virus will continue to infect humans regularly, it is critical to understand the role of alternative receptors for SARS-CoV-2 in the oral mucosa, the potential portal of SARS-CoV-2 entry, to develop anti-viral therapeutics and strategies to dampen virus-mediated immune activation and disease outcomes, especially as regards emerging variants.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15239", "attributes": { "award_id": "1R34MH134935-01A1", "title": "The Latino Youth and Family Empowerment Study – III (LYFE-III): Bringing to Scale a Culturally-Adapted and Evidence-Based Intervention for Latino Families", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 11081, "first_name": "Mary", "last_name": "Rooney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2027-06-30", "award_amount": 255855, "principal_investigator": { "id": 31823, "first_name": "Cory Lamoine", "last_name": "Cobb", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31824, "first_name": "CHARLES R", "last_name": "MARTINEZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1643, "ror": "", "name": "TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The Latino Youth and Family Empowerment Study – III (LYFE-III): Bringing to Scale a Culturally- Adapted and Evidence-Based Intervention for Latino Families Project Summary/Abstract Latino families experience chronic stressors that place them at high risk for mental health problems. Latino youth not only report higher prevalence rates of depression than most other racial and ethnic groups, but they also report the highest rates of suicidal ideation and attempts across all minority groups. In addition, COVID-19 disparately impacted Latino families and compounded the many stressors and mental health issues that Latino families face. Indeed, Latino youth reported among the highest rates of loneliness and poor mental health during the pandemic. Despite high risk for mental health problems, Latino families in the U.S. are underserved in the mental health care system due to persistent barriers to accessing services, including discrimination, treatment costs, language barriers, and stigma. This lack of access to mental health resources for Latino families was exacerbated by the pandemic. The many stressors faced by Latino families, the havoc wreaked by COVID-19, and the lack of access to mental health care set a precarious foundation for the development of mental health problems among Latino youth, and effective preventive interventions are greatly needed. The Latino Youth and Family Empowerment – III study (LYFE-III) proposed here is an extension of the present team’s preliminary work (LYFE-I and LYFE-II studies) funded by NIH and represents a unique opportunity to adapt, scale, and evaluate the efficacy of an online version of Nuestras Familias with Latino youth who are at risk for mental and behavioral health problems following the pandemic. The scientific premise of this study is based on: (a) high prevalence rates of mental and behavioral health issues among Latino youth; (b) the disparate impact of COVID-19 on Latino families; (c) the vital role of parents in their youth’s mental health; and (d) persistent barriers among Latino families to accessing mental health treatment. Accordingly, the following two aims are proposed: (1) to adapt Nuestras Familias to an online format that can be widely accessed by underserved Latino families. This aim includes the fidelity monitoring, enhancing efficiency, and manualization of intervention content; and (2) conduct a hybrid type 1 effectiveness- implementation randomized controlled trial to (a) test the online program’s promise while evaluating target mechanisms of action (i.e., parenting practices) and their effects on youth mental health outcomes; and (b) evaluate the feasibility, appropriateness, and acceptability of the online version of the Nuestras Familias. The present approach is innovative because it is among the first to harness digital technology to provide Latino parents with accessible evidence-based mental health resources following a global pandemic. Further, the technology underlying the intervention will be refined through a process of iterative feedback with Latino families and community partners to increase the uptake, useability, and acceptability of the intervention. These contributions will be significant because they will take an important step toward advancing mental health equity among vulnerable Latino families through increasing access to critical mental and behavioral health resources.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15240", "attributes": { "award_id": "1K23HL168161-01A1", "title": "K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24472, "first_name": "LISBETH A", "last_name": "WELNIAK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2029-07-31", "award_amount": 160518, "principal_investigator": { "id": 31825, "first_name": "Susan", "last_name": "Conway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1167, "ror": "", "name": "CHILDREN'S RESEARCH INSTITUTE", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching goal of this proposal is the development of the candidate into an independent investigator in the field of immune modulatory cell therapy for critically ill children, particularly those post hematopoietic stem cell transplant (HSCT). With her clinical and research background in pediatric critical care and T cell immunotherapy, she is ideally positioned to fully realize the benefits of an NIH Mentored Career Development Award. This research proposal seeks to establish the safety and preliminary efficacy of adoptive immunotherapy with donor-derived SARS-CoV-2-specific T cells (CST) for prophylaxis against SARS-CoV-2 infection in patients post HSCT by conducting an FDA- and IRB-approved phase I clinical trial (NCT 05141058) and to develop CSTs genetically engineered to maintain antiviral activity in the presence of the commonly used lymphodepleting agent, alemtuzumab. The specific aims of the proposal are: 1) to determine whether infusion of donor-derived CSTs safely enhances antiviral immunity to SARS-CoV-2 in patients early (<4 months) post HSCT, and 2) to genetically engineer CSTs to retain antiviral activity in vitro in the presence of alemtuzumab. Together, these aims will establish the safety and preliminary efficacy of CST prophylaxis in the post HSCT population and lay the foundation for a “next generation” of virus-specific T cells (VST) engineered to resist immunosuppressive peri- transplant drugs. In addition, they will develop the candidate's expertise in T cell immunobiology, high throughput sequencing, gene editing, and early phase clinical trials. The candidate has assembled an outstanding advisory team who are highly qualified to guide her in the pursuit of her career and research goals. Her primary mentor and co-mentor, Drs. Catherine Bollard and Michael Keller, are world-renowned experts in immune modulatory cellular therapy and T cell immunobiology. Dr. Matthew Porteus, a pioneer in the field of gene therapy, will guide her work developing genetically engineered CSTs. In addition, Dr. Patrick Hanley, Director of the Good Manufacturing Processes Laboratory at Children's National Hospital, will oversee production of the CST product (IND 27588); Dr. Rick Jones will advise and oversee trial conduct at Johns Hopkins Medical Institutions (JHMI); and Dr. Wei Li will provide bioinformatic support for both CRISPR and high throughput sequencing experiments. A selection of focused coursework and seminars will facilitate investigator independence by the end of the award period. The candidate will benefit from a superb academic environment and extensive resources available through the Center for Cancer and Immunology Research, the Genetic Medicine Research Center, and the Clinical and Translational Science Institute at Children's National, as well as from in-person training in gene editing in the Porteus laboratory. In summary, this proposal describes a plan that is relevant, feasible, and will provide the necessary mentorship and training to promote the candidate's development into an independent clinician scientist in the field of cellular immune modulatory therapy.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15241", "attributes": { "award_id": "2R01NR016732-06", "title": "A clinician-in-the-loop smart environment to support management of chronic health conditions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 31607, "first_name": "Karen Marie", "last_name": "Mcnamara", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-08", "end_date": "2029-05-31", "award_amount": 418620, "principal_investigator": { "id": 31826, "first_name": "Diane Joyce", "last_name": "Cook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31827, "first_name": "Roschelle", "last_name": "Fritz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT As the population of individuals 65+ grows, so too will the number of individuals who struggle to manage chronic health conditions. Exacerbations, or sudden symptom worsening, of chronic conditions place a burden on the health care system and cause decreased quality of life and accelerated decline. Forecasting health exacerbations can prevent life-threatening events or limit their impact. The long-term goal of this work is to create a clinician-in-the-loop (CIL) smart environment that empowers individuals in managing their chronic health conditions. Our proposed CIL framework partners clinical expertise with pervasive computing and machine learning. In this system, sensor data are collected continuously by ambient and wearable sensors. Our ML algorithms extract behavior markers to show to a clinician. Behavior changes are detected due to internal (i.e., condition exacerbation) or external (i.e., wildfire smoke, shutdown due to COVID-19 pandemic) events. Trained by clinicians, prediction of future condition exacerbations and health states are generated with corresponding reliability scores. Correspondingly, clinicians will provide summaries of observed behavior, reasons to confirm likely exacerbations, and recommendations to prevent health events. These summaries are used to train a language model that will provide interactive explanations of future data and ML predictions. Data are collected continuously by ambient sensors in the smart home and wearable sensors in Apple watches to validate the findings and provide more complete monitoring. From smartwatch sensors, we will analyze the predictive relationship between external events, social determinants of health, socialization, environment quality, behavior, and health state. The result of these steps is an automated technology that can assist with self-management of chronic conditions and monitor the impact of interventions. The proposed aims will be validated using data collected in our prior study for n=44 older adults and in a new data collection with n=20 older adults. Participants in the restrospective study with historic data and prospective study with new data will be older adults age 50+ living in independent homes who are managing one or more chronic health conditions. Expanding the smart environment to encompass ambient sensors and wearable sensors increases the accessibility of the technology for underserved communities and, when used in combination, improves model robustness through joint prediction. Although clinical oversight of patient health will always be valuable, the technology can provide an “informatics triage” that allows a clinician to remotely monitor a greater number of individuals at a time and provide valuable information to the individual to assist in self-management. Outcomes of this proposed study include open-source software for forecasting condition exacerbations, software to train language models from clinician input, and the corresponding trained models; results of analyses linking external influences, socialization, behavior, and health; apps for collecting ambient and wearable data; and data that will be prepped for integration into the NIH RWDP platform.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15242", "attributes": { "award_id": "1R01MH129549-01A1", "title": "Sleep to Reduce Incident Depression Effectively in Peripartum - (STRIDE P)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 11081, "first_name": "Mary", "last_name": "Rooney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2028-02-29", "award_amount": 992063, "principal_investigator": { "id": 31828, "first_name": "CHRISTOPHER L", "last_name": "DRAKE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31829, "first_name": "David Addison", "last_name": "Kalmbach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2066, "ror": "https://ror.org/0599cab37", "name": "Henry Ford Health + Michigan State University Health Sciences", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Abstract. Perinatal depression (PND) affects nearly 20% of pregnant and postpartum women, with estimates soaring above 30% during the COVID-19 pandemic. Prospective data show insomnia precedes over half of PND incidence and relapse cases more than doubling risk for major depression. This is highly significant to a large segment of the pregnant population as ~20% of women meet diagnostic criteria for insomnia disorder by the end of pregnancy. Fortunately, insomnia is a modifiable risk factor for PND, and insomnia may serve as an entry point to prevent PND incidence and relapse. Although cognitive-behavioral therapy for insomnia (CBTI) alleviates insomnia during pregnancy, it yields modest effects on PND and undertreats cognitive arousal (heightened cognitive activity, particularly in the forms of rumination and worry at night). Our team identified cognitive arousal as a promising candidate factor for alleviating insomnia and preventing depression via insomnia therapy. Indeed, undertreatment of cognitive arousal in pregnancy is associated with insomnia non-remission and continued depression after therapy. Moreover, patient stakeholders identify ‘calming a busy mind at night’ as a critical target for improving sleep and wellbeing during pregnancy. In effort to enhance alleviation of cognitive arousal to optimize clinical outcomes, we developed Perinatal Understanding of Mindful Awareness for Sleep (PUMAS). PUMAS places behavioral sleep strategies within a mindfulness intervention framework with all components tailored specifically for pregnancy. RCT data show that PUMAS yields large effects on insomnia, depression, and cognitive arousal relative to control, whereas CBTI alleviates insomnia but has mixed or minimal effects on PND and cognitive arousal. Our R34 pilot RCT shows PUMAS patients are more satisfied with their care than pregnant women treated with CBTI, and that clinic leadership and providers rate PUMAS as acceptable, feasible, and appropriate for implementation. PUMAS has immense potential to change the management of prenatal insomnia and to curb PND rates via preventive care. We propose a large-scale RCT of 500 women with DSM-5 insomnia disorder (without PND) who are randomized to PUMAS or sleep education control. We will evaluate the effectiveness of PUMAS for alleviating insomnia and preventing PND across pregnancy and the first postpartum year. This project will not only test PUMAS effectiveness for insomnia and PND prevention but will also investigate whether PUMAS engages a key candidate mechanism (high cognitive arousal) that is operative for addressing these clinical outcomes in the effectiveness context (PAR-21-130). We will recruit pregnant women from the 23 women’s health clinics and 5 maternal-fetal medicine clinics across HFH, centrally located in Metro Detroit. This application directly addresses research objectives under PAR-21-130, which states: “preventive and therapeutic interventions [should target] factors that have been empirically associated with risk for or the etiology, maintenance, severity/course of the disorder or condition of interest.”", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15243", "attributes": { "award_id": "1U19AI181968-01", "title": "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31830, "first_name": "Genevieve Anne", "last_name": "Holzapfel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-20", "end_date": "2027-07-31", "award_amount": 33116067, "principal_investigator": { "id": 31831, "first_name": "PHILIP Louis", "last_name": "FELGNER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 971, "ror": "", "name": "UNIVERSITY OF CALIFORNIA-IRVINE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Overall: The UCI Vaccines for Pandemic Preparedness Center (VPPC) The Mission: \"To contribute to human health and well-being by developing agile, safe, effective and accessible vaccines that protect the vulnerable against future pathogens of pandemic importance and by educating the next generation of vaccine scientists that will tackle such challenges.” Joshua Lederberg envisioned the world as a battlefield between microbes and man, famously saying, “The future of humanity and microbes likely will unfold as episodes of a suspense thriller that could be titled Our Wits Versus Their Genes” (Lederberg, 2000). Although the genes of the microbial world have been evolving much longer than our wits, we have come up with efficient ways to respond to infectious diseases, but regrettably evolving microorganisms keep managing to challenge and outsmart us. The latest COVID episode in this series sensitized the world again to the importance of learning from the outbreak experience and challenges us to better prepare for the next one. The 100 Days Mission (100DM), endorsed by government and non-government organizations worldwide is a proposed response to the next “Disease X” by making safe, and effective vaccines available within 100 days of the pathogen’s identification. Achieving that goal could defuse the threat of a pathogen with pandemic potential. The International Pandemic Preparedness Secretariate (IPPS), the Coalition for Epidemic Preparedness Innovations (CEPI), the HHS Administration for Strategic Preparedness and Response (ASPR Next) and the NIH/NIAID have embraced the concept of studying prototype pathogens as a critical element of preparedness. By developing vaccines on rapid-response platforms against examples of a given viral genus or family, researchers can address scientific challenges characteristic of that family in advance, providing an important head start on developing vaccines against related threats. Universal programmable vaccine platforms that can be rapidly employed against broad virus families can be evaluated in clinical trials to provide confidence in their safety, and manufacturing, and regulatory considerations can be managed ahead of the next outbreak. The UC Irvine Vaccines for Pandemic Preparedness Center (VPPC) aims to conduct basic and translational research to develop vaccines against prototype members of the Bunyavirus, Paramyxovirus and Picornavirus families with demonstrated immunogenicity and efficacy in animal models. Two universal, programmable, rapid response vaccine platforms will be characterized and compared in this study: the i) Adjuvanted Recombinant Protein (ARP) Vaccine, and ii) mRNA/Lipid Nanoparticle (LNP) Vaccine. Such prototype vaccines will need to be tested in advance, at a minimum, for clinical safety and immunogenicity, and efficacy where possible, so that emerging viruses in the same family can be rapidly and safely deployed. Gathering such data and experience will build confidence in these rapid response platforms and inform regulators as they make decisions about the emergency authorization of vaccines against related pathogens.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15244", "attributes": { "award_id": "1F30MH136702-01", "title": "Mobile Crisis Workforce Pipeline: Meeting the Needs of Illinois", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26585, "first_name": "Maggie", "last_name": "Sweeney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 41241, "principal_investigator": { "id": 31832, "first_name": "Jeremy David", "last_name": "Fine", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has underscored the need for robust mental health services in the United States (US). In contrast, the mental health workforce is shrinking. Lack of resources has led to patients “boarding” for days in the Emergency Department (ED) while they await inpatient hospital beds. In attempt to address these issues, federal and state policymakers have recently enacted policies to improve the Nation’s mental health crisis care infrastructure. One such law changed the phone number for the National Suicide Prevention Lifeline (NSPL) to “988.” This simple number created an unprecedented demand for psychiatric crisis professionals who can respond to callers deemed to be at imminent risk of harm to themselves or others. The Substance Abuse and Mental Health Services Administration (SAMHSA) has put forth Mobile Crisis Units (MCUs) as a solution to this problem. MCUs are a psychiatric service that meets individuals in crisis wherever they are in the community to de-escalate, triage, and refer them to additional services. They represent a way to ensure NSPL callers can receive care in the least restrictive setting, thus preventing unnecessary hospitalization. According to the SAMSHA model, MCUs are two person teams composed of a mental health professional and a certified peer provider (i.e. a Certified Recovery Support Specialist [CRSS]). Many states must now significantly expand their mental health crisis workforce to effectively meet the needs of their citizens and follow SAMHSA’s recommendations. Illinois (IL) is an example of a state that has enacted policies designed to fill this gap. Two programs, the CRSS Success Program (CRSS-SP) and Program 590, were designed to increase the workforce of CRSSs able to work on MCUs and increase the number of MCUs in the state, respectively. These relatively new programs have yet to be evaluated on how effectively they are able to grow the state’s MCU workforce. Systems thinking is a framework that seeks to solve complex problems by understanding how parts of a system function to produce outcomes. Methods grounded in systems thinking, such as Group Model Building (GMB) and Simulation Modeling (SM), have a proven track record for effectively generating policies that solve healthcare workforce issues, but they have yet to be used in the context of the MCU workforce pipeline. The objectives of this study are therefore to 1) use GMB to create a map of Illinois’s MCU workforce pipeline system and evaluate if this method is effective in this context, 2) evaluate data from the CRSS-SP and Program 590 to determine which factors increase the likelihood that CRSSs and MHPs obtain and retain employment at MCUs, and 3) use SM to test policies that will help the state meet its MCU workforce needs. The recommendations generated by this study will be given to state government officials so they can be used to improve the lives of individuals in IL experiencing mental health crises.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15247", "attributes": { "award_id": "1U01AI184159-01", "title": "A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8447, "first_name": "Jeffrey S.", "last_name": "Rice", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2027-05-31", "award_amount": 1225013, "principal_investigator": { "id": 31833, "first_name": "Gary S", "last_name": "Gilkeson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 7373, "first_name": "Ignacio E.", "last_name": "Sanz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31834, "first_name": "DIANE L", "last_name": "KAMEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1179, "ror": "https://ror.org/012jban78", "name": "Medical University of South Carolina", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "Cellular therapies for the treatment of autoimmune diseases offers a novel treatment option with possible increased efficacy and decreased toxicity. We are performing the first multi-center double blind placebo controlled dose escalation trial of mesenchymal stromal cells (MSCs) for standard of care refractory lupus. This Phase II trial is based on promising data from open label trials in China and our own Phase I trial. Response rates very from 65-75% in reports from China while we saw an SRI-4 response in 5/6 patients we treated with umbilical cord derived MSCs. There are nine US centers participating in the MiSLE trial. Due to impact of the COVID-19 pandemic, we were unable to reach our goal of 81 patients during a previously funded NIAID U01 grant that expired in March, 2023. Sixty two of the 81 patients are either randomized or treated as of now. We were meeting our benchmarks of 1.98 patients per month until a COVID induced shutdown the trial for months. We are recruiting patients at this rate again. In the trial to this point, we have had no safety signals, no issues with infrastructure and patients meeting the primary study endpoint of the SRI-4. This is a critical trial to finish to definitely show if there is a treatment effect of MSCs in lupus and to delineate the mechanisms by which MSCs impact disease. In the Phase I trial we found marked impacts on extra follicular derived B cells. We are seeing similar trends in preliminary analysis of the Phase II trial, though we are blinded as to treatment group. We have introduced novel methods of multi-parameter statistical analysis to enhance detecting a treatment effect. In mechanistic studies we will complete the analyses of B and T cell subsets, receptor diversity and epigenetics over the course of the trial. Based on the development of new technology, we will perform CyTOF on mononuclear cell populations, Cite Seq single cell analysis and plasma microbiome assays. These assays will be performed at weeks 0, 4, 8 and 24. We have sufficient stored samples to perform the proposed assays. This highly impactful trial will provide important insight into changes over time of key immune mediators of lupus, perhaps allowing pre-treatment identification of patients most likely to respond to MSC treatment.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15248", "attributes": { "award_id": "1F31AI176851-01A1", "title": "Investigating the potential of wastewater surveillance data to improve SARS-CoV-2 dynamical modeling and forecasting", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 36053, "principal_investigator": { "id": 31835, "first_name": "Emma May", "last_name": "Gorin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Policy makers, researchers and public health officials rely on forecasts from infectious disease models to anticipate resource use, assess risk, and plan public health interventions. In order to effectively and accurately predict future cases and hospitalization rates of COVID-19, these models depend on high quality data on infections in the population. However, as clinical testing becomes less reliable with the ubiquity of at-home antigen tests and the frequency of case reporting is decreased in many states, there is a critical need to identify alternative data sources. Wastewater-based surveillance is a promising supplement to traditional data sources for monitoring infection at the population level: it is anonymous, cost-effective, and unaffected by variation in clinical testing and reporting. It also reflects infections in the population days or weeks sooner than they would be captured by reported cases or hospitalizations. While there is ample evidence that wastewater concentrations of SARS-CoV-2 correlate with COVID-19 cases, wastewater data have rarely been used to inform modeling and forecasting, and the benefit of incorporating wastewater surveillance data into data-driven dynamical models for forecasting has not been rigorously assessed. The goal of this project is to leverage a rich dataset from the New York State Wastewater Surveillance Network to evaluate the potential for wastewater surveillance data to improve inference of SARS-CoV-2 transmission dynamics. Partnering with the New York State Wastewater Surveillance Network, which includes over 150 wastewater treatment plants across 61 counties of New York State and represents a population of more than 15 million, provides a unique opportunity to investigate the value of wastewater surveillance for modeling at a larger scale. We will build on an existing metapopulation model developed by the Shaman Lab to test how inference and forecasting of transmission dynamics can be improved by integrating wastewater data. In other words, we will use retrospective data from New York State to rigorously assess: can we predict future cases more accurately by using wastewater data to inform our models? This study would be the first that we know of to use a metapopulation structure, which considers population movement, to model SARS-CoV-2 with wastewater surveillance data. By more realistically modeling how human populations move and mix, this model structure can better capture real-world transmission dynamics. This will be crucial to realistically evaluate whether wastewater data can be relied on in the future to forecast COVID-19 incidence, which will be particularly important as clinical testing fluctuates and case reporting becomes sparser. It may also motivate the application of wastewater-based modeling to other pathogens detectable in feces, facilitating the development of prompt, cost-effective forecasts of other communicable diseases in the future.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1442, "count": 14420 } } }